The rate declines from 0.5-1% per week during titration to 0.2-0.3% per week at maintenance
Biochem J (2007) 401(3):64550
Because it is not yet FDA-approved, no prescribing label exists to guide supplement co-administration, which makes independent clinical judgment essential
This dual-agonism activity of tirzepatide may contribute to the greater weight reduction observed with tirzepatide than with semaglutide, a monoagonist used in the current trial. The results show that as weight reduction increased there were greater improvements in cardiometabolic risk factors, including blood pressure, and blood fat and sugar levels, with both treatments consistent with previous reports
[1] While the FDA prescribing information does not specifically address antibiotics with semaglutide, no clinically meaningful interactions have been identified to date
Covered in colorful bead-like scales, the Gila monster spends most of its life hidden in burrows, emerging mainly to hunt or bask